Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 697-88-1 | MDL No. : | MFCD00025162 |
Formula : | C6H4BrCl2N | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | NPQBZKNXJZARBJ-UHFFFAOYSA-N |
M.W : | 240.91 | Pubchem ID : | 69680 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 0.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 48.57 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.11 cm/s |
Log Po/w (iLOGP) : | 2.18 |
Log Po/w (XLOGP3) : | 3.75 |
Log Po/w (WLOGP) : | 3.35 |
Log Po/w (MLOGP) : | 3.41 |
Log Po/w (SILICOS-IT) : | 3.1 |
Consensus Log Po/w : | 3.16 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -4.14 |
Solubility : | 0.0174 mg/ml ; 0.0000724 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -3.99 |
Solubility : | 0.0247 mg/ml ; 0.000103 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.13 |
Solubility : | 0.0179 mg/ml ; 0.0000743 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 1.69 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | Stage #1: With hydrogenchloride; sodium nitrite In water at 0℃; Stage #2: at 70℃; for 0.5 h; |
Synthesis of compound 9.2. To a suspension of compound 9.1 (7.0 g, 29 mmol, 1.0 equiv), in water (35 mL) was added cone, hydrochloric acid (14 mL). The suspension was cooled to 0 °C then sodium nitrite (2.2 g, 31.96mmol, 1.1 equiv) in water (7mL) was added dropwise at 0 °C and the reaction mixture was stirred for 30 minutes. In another flask, a solution of copper (I) cyanide (3.11 g, 37.86mmol, 1.2 equiv) and sodium cyanide (2.13 g, 43.5mmol, 1.5 equiv) in water (35mL) was heated to 70°C. The diazonium salt mixture was neutralized by solid sodium bicarbonate and added portion wise to the cyanide mixture at 70°C. The mixture was heated at 70 °C for 30 minutes. Upon completion, the mixture was cooled to room temperature and extracted with toluene. The organic layers were combined, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude material which was purified via flash column chromatography to furnish compound 9.2 (1.6g, 48percent). |
[ 16429-44-0 ]
5-Bromo-3-chlorobenzene-1,2-diamine
Similarity: 0.87
[ 16429-44-0 ]
5-Bromo-3-chlorobenzene-1,2-diamine
Similarity: 0.87